Pre-earnings options volume in Annovis Bio Inc is normal with calls leading puts 4:3. Implied volatility suggests the market is anticipating a move near 5.8%, or 45c, after results are released. Median move over the past eight quarters is 4.1%.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANVS:
- Largest borrow rate increases among liquid names
- Annovis Bio initiated with a Buy at EF Hutton
- Annovis Bio announces preclinical data on buntanetap with GLP-1 agonist
- Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
- Annovis Bio secures U.S. patent for treatment of acute TBI with buntanetap